Avidity Biosciences Stock Alpha and Beta Analysis
| RNA Stock | USD 31.11 1.02 3.17% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Avidity Biosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Avidity Biosciences over a specified time horizon. Remember, high Avidity Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Avidity Biosciences' market risk premium analysis include:
Beta 1.26 | Alpha 0.0148 | Risk 3.32 | Sharpe Ratio (0.02) | Expected Return (0.06) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Avidity |
Avidity Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Avidity Biosciences market risk premium is the additional return an investor will receive from holding Avidity Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Avidity Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Avidity Biosciences' performance over market.| α | 0.01 | β | 1.26 |
Avidity Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Avidity Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Avidity Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Avidity Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Avidity Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Avidity Biosciences shares will generate the highest return on investment. By understating and applying Avidity Biosciences stock market price indicators, traders can identify Avidity Biosciences position entry and exit signals to maximize returns.
Avidity Biosciences Return and Market Media
The median price of Avidity Biosciences for the period between Sat, Dec 14, 2024 and Fri, Mar 14, 2025 is 31.18 with a coefficient of variation of 7.33. The daily time series for the period is distributed with a sample standard deviation of 2.31, arithmetic mean of 31.53, and mean deviation of 1.81. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 25000 shares by Teresa McCarthy of Avidity Biosciences at 14.22 subject to Rule 16b-3 | 12/16/2024 |
2 | Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA | 12/31/2024 |
3 | Insider Trading | 01/06/2025 |
4 | Disposition of 2032 shares by Hughes Steven George of Avidity Biosciences at 28.5906 subject to Rule 16b-3 | 01/21/2025 |
5 | Disposition of 5629 shares by Kathleen Gallagher of Avidity Biosciences at 30.1609 subject to Rule 16b-3 | 01/22/2025 |
6 | Disposition of 1221 shares by Teresa McCarthy of Avidity Biosciences at 28.5968 subject to Rule 16b-3 | 01/23/2025 |
7 | Nucleotides Market Research Report 2025-2033 Analysis by Type, Technology, Form, Application and Region | 01/29/2025 |
8 | Disposition of 5875 shares by Kathleen Gallagher of Avidity Biosciences at 16.65 subject to Rule 16b-3 | 02/03/2025 |
9 | EnPlusOne Biosciences Raises 10M in Financing | 02/19/2025 |
10 | Avidity Biosciences Inc Announces Participation in Upcoming Investor Conferences | 02/25/2025 |
11 | Avidity Biosciences GAAP EPS of -0.80 misses by 0.02, revenue of 2.97M beats by 1.23M | 02/27/2025 |
12 | Avidity Biosciences Honors Rare Disease Day and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases | 02/28/2025 |
13 | Disposition of 5875 shares by Kathleen Gallagher of Avidity Biosciences at 14.7 subject to Rule 16b-3 | 03/03/2025 |
14 | Cofactor Genomics Announces the Expansion of OncoPrism into Colorectal, Breast, Bladder, and Kidney Cancer | 03/05/2025 |
15 | Acquisition by Kathleen Gallagher of 5875 shares of Avidity Biosciences at 16.65 subject to Rule 16b-3 | 03/06/2025 |
16 | Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to Develop Cell-Targeted RNA Medicines | 03/11/2025 |
17 | NTx Establishes Scientific Advisory Board with Distinguished Leaders in Oncology | 03/13/2025 |
About Avidity Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Avidity or other stocks. Alpha measures the amount that position in Avidity Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Dividend Yield | 8.9E-5 | 7.9E-5 | Price To Sales Ratio | 297.77 | 423.6 |
Avidity Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Avidity Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Avidity Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Avidity Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Avidity Biosciences. Please utilize our Beneish M Score to check the likelihood of Avidity Biosciences' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Avidity Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Avidity Biosciences Backtesting, Avidity Biosciences Valuation, Avidity Biosciences Correlation, Avidity Biosciences Hype Analysis, Avidity Biosciences Volatility, Avidity Biosciences History and analyze Avidity Biosciences Performance. For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Avidity Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.